'Unheard of' responses to bluebird CAR-T therapy seen in myeloma study

Dec 10 (Reuters) - More than half of patients with advanced multiple myeloma who had run out of therapeutic options remained in complete remission after receiving bluebird bio Inc's experimental gene-modifying immunotherapy in a small, early stage study, according to updated data released on Sunday.